Patents Assigned to Institute of Molecular Biology
  • Patent number: 10385138
    Abstract: The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: August 20, 2019
    Assignees: Ludwig Institute for Cancer Research Ltd., Sloan-Kettering Cancer Institute, Institute of Molecular Biology and Genetics National Academy of Science of Ukraine
    Inventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
  • Patent number: 9701755
    Abstract: The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: July 11, 2017
    Assignees: Ludwig Institute for Cancer Reserach Ltd., Sloan Kettering Cancer Institute, Institute of Molecular Biology and Genetics National Academy of Science of Ukraine
    Inventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
  • Patent number: 9045533
    Abstract: The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: June 2, 2015
    Assignees: Ludwig Institute for Cancer Research Ltd, Institute for Molecular Biology and Genetics National Academy of Science of Ukraine, Sloan Kettering Cancer Institute
    Inventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
  • Patent number: 8603474
    Abstract: The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: December 10, 2013
    Assignees: Ludwig Institute for Cancer Research, Ltd., Institute of Molecular Biology and Genetics National Academy of Science of Ukraine, Sloan-Kettering Institute for Cancer Research
    Inventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
  • Publication number: 20030166235
    Abstract: The present invention relates to nucleic acids comprising a nucleotide sequence encoding at least a portion of an enzyme which catalyzes the synthesis of chitin in arthropods, inhibitors directed to said enzyme, and a method for developing said inhibitors.
    Type: Application
    Filed: June 26, 2002
    Publication date: September 4, 2003
    Applicant: Foundation for Research and Technology - Hellas Institute of Molecular Biology and Biotechnology
    Inventors: George Thireos, Dimitris Kafetzopoulos
  • Patent number: 6506727
    Abstract: It has been found that the growth factor PDGF, when used in combination with another growth factor such as IGF-I, acts synergistically with the other factor to promote neuronal regeneration.
    Type: Grant
    Filed: February 18, 1994
    Date of Patent: January 14, 2003
    Assignee: Institute of Molecular Biology, Inc.
    Inventors: Hans-Arne Hansson, Samuel E. Lynch, Harry N. Antoniades
  • Patent number: 6297040
    Abstract: Disclosed is the DNA sequence of an enzyme which catalyzes the conversion of chitin to chitosan. The enzyme exhibits substantial homology to the rhizobial nodB protein.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: October 2, 2001
    Assignee: Institute for Molecular Biology & Biotechnology/FORTH
    Inventors: George Thireos, Dimitri Kafetzopoulos
  • Patent number: 6225121
    Abstract: Disclosed are isolated transposable elements, or isolated DNA sequences which encode a transposase protein (or a portion of a transposase protein). The isolated transposable elements or the isolated DNA sequences being characterized by the ability to hybridize to the DNA sequence of Minos-1. The invention also relates to a purified transposase protein, or peptide fragments thereof, encoded by such DNA sequences. Such transposable are useful in methods for the stable introduction of a DNA sequence of interest into a cell. The invention further relates to transgenic animals, gene tagging and insertional mutagenesis produced by such methods. The sequence information disclosed herein is useful in the design of oligonucleotide primers which are useful for the isolation of related members of the Tc-1 family of transposable elements.
    Type: Grant
    Filed: April 27, 1998
    Date of Patent: May 1, 2001
    Assignee: Institute of Molecular Biology and Biotechnology/FORTH
    Inventors: Charalambos Savakis, Gerald H. Franz, Athanasios Loukeris, Apostolos G. Klinakis
  • Patent number: 6159717
    Abstract: Disclosed are isolated transposable elements, or isolated DNA sequences which encode a transposase protein (or a portion of a transposase protein). The isolated transposable elements or the isolated DNA sequences being characterized by the ability to hybridize to the DNA sequence of Minos-1. The invention also relates to a purified transposase protein, or peptide fragments thereof, encoded by such DNA sequences. Such transposable are useful in methods for the stable introduction of a DNA sequence of interest into a cell. The invention further relates to transgenic animals produced by such methods. The sequence information disclosed herein is useful in the design of oligonucleotide primers which are useful for the isolation of related members of the Tc-1 family of transposable elements.
    Type: Grant
    Filed: November 18, 1998
    Date of Patent: December 12, 2000
    Assignee: Institute for Molecular Biology and Biotechnology/Forth
    Inventors: Charalambos Savakis, Gerald H. Franz
  • Patent number: 6004795
    Abstract: Disclosed is the DNA sequence of an enzyme which catalyzes the conversion of chitin to chitosan. The enxyme exhibits substantial homology to the rhizobial nodB protein.
    Type: Grant
    Filed: March 25, 1996
    Date of Patent: December 21, 1999
    Assignee: Institute for Molecular Biology and Biotechnology
    Inventors: George Thireos, Dimitri Kafetzopoulos
  • Patent number: 5840865
    Abstract: Disclosed are isolated transposable elements, or isolated DNA sequences which encode a transposase protein (or a portion of a transposase protein). The isolated transposable elements or the isolated DNA sequences being characterized by the ability to hybridize to the DNA sequence of Minos-1. The invention also relates to a purified transposase protein, or peptide fragments thereof, encoded by such DNA sequences. Such transposable are useful in methods for the stable introduction of a DNA sequence of interest into a cell. The invention further relates to transgenic animals produced by such methods. The sequence information disclosed herein is useful in the design of oligonucleotide primers which are useful for the isolation of related members of the Tc-1 family of transposable elements.
    Type: Grant
    Filed: September 20, 1995
    Date of Patent: November 24, 1998
    Assignee: Institute of Molecular Biology and Biotechnology/FORTH
    Inventors: Charalambos Savakis, Gerald H. Franz, Athanasios Loukeris
  • Patent number: 5656605
    Abstract: The invention relates generally to a system for promoting regeneration of a damaged nerve. In particular, the invention comprises: (1) a guide tube constructed to be attached to the damaged nerve; (2) guiding filaments disposed within the guide tube; and, (3) a therapeutic composition enclosed by the guide tube. Both the guide tube and the guiding filaments are composed of biologically compatible materials, while the therapeutic composition contains a nerve-growth-stimulating agent dispersed in a matrix-forming material. During treatment, the guide tube is inserted between the ends of lesioned nerves, resulting in the stimulation of axon growth.
    Type: Grant
    Filed: January 26, 1994
    Date of Patent: August 12, 1997
    Assignee: Institute of Molecular Biology, Inc.
    Inventors: Hans-Arne Hansson, Michael R. Wells, Samuel E. Lynch, Harry N. Antoniades
  • Patent number: 5569582
    Abstract: Disclosed herein are methods, primers, probes, and kits for the rapid amplification and detection of nucleic acids. The invention provides improved methods for amplifying small amounts of nucleic acid in a sample in which the amplification steps are conducted at the same temperature, or alternatively, at two different temperatures. The invention also provides improved methods for detecting the amplified nucleic acid in which the detection signal is boosted. Related probes and test kits are also provided. The invention is particularly useful in the detection of HIV-1.
    Type: Grant
    Filed: December 22, 1993
    Date of Patent: October 29, 1996
    Assignee: Institute of Molecular Biology & Technology
    Inventors: Nectarios Tavernarakis, George Hatzidakis, Elias Krambovitis
  • Patent number: 5525502
    Abstract: Disclosed is the DNA sequence of an enzyme which catalyzes the conversion of chitin to chitosan. The enxyme exhibits substantial homology to the rhizobial nodB protein.
    Type: Grant
    Filed: December 7, 1992
    Date of Patent: June 11, 1996
    Assignee: Institute for Molecular Biology & Biotechnology/FORTH
    Inventors: George Thireos, Dimitri Kafetzopoulos
  • Patent number: 5516699
    Abstract: A method of diagnosing severity of periodontal disease or peri-implant disease in a human patient, involving a) obtaining a sample of tissue or gingival crevicular or other fluid from the mouth of said patient, or a blood or urine sample from the patient, and b) measuring a pyridinoline crosslinked compound in the sample as a measure of severity of disease.
    Type: Grant
    Filed: February 16, 1994
    Date of Patent: May 14, 1996
    Assignees: Institute of Molecular Biology, Inc., President and Fellows of Harvard College
    Inventors: William V. Giannobile, Ray C. Williams, Samuel E. Lynch
  • Patent number: 5348874
    Abstract: Disclosed are isolated transposable elements, or isolated DNA sequences which encode a transposase protein (or a portion of a transposase protein). The isolated transposable elements or the isolated DNA sequences being characterized by the ability to hybridize to the DNA sequence of Minos 1 under stringent hybridization conditions. The invention also relates to a purified transposase protein, or peptide fragments thereof, encoded by such DNA sequences. Such transposable are useful in methods for the stable introduction of a DNA sequence of interest into a eukaryotic cell. The sequence information disclosed herein is useful in the design of oligonucleotide primers which are useful for the isolation of related members of the Tc-1 family of transposable elements.
    Type: Grant
    Filed: September 14, 1992
    Date of Patent: September 20, 1994
    Assignee: Institute for Molecular Biology and Biotechnology/FORTH
    Inventors: Charalambos Savakis, Gerald H. Franz, Athanasios Loukeris
  • Patent number: 5256644
    Abstract: Healing an external wound of a mammal by administering to the mammal a composition containing purified Insulin-like growth factor-I and purified transforming growth factor beta.
    Type: Grant
    Filed: March 25, 1992
    Date of Patent: October 26, 1993
    Assignees: Institute of Molecular Biology, Inc., President and Fellows of Harvard College
    Inventors: Harry N. Antoniades, Samuel E. Lynch
  • Patent number: 5219749
    Abstract: Chitin deacetylase, the enzyme that catalyzes the hydrolysis of acetamide groups of N-acetylglucosamine in chitin, was purified to homogeneity from mycelial extracts of the fungus Mucor rouxii. In addition, immunoglobulin specifically reactive with chitin deacetylase has been produced and purified.
    Type: Grant
    Filed: October 9, 1991
    Date of Patent: June 15, 1993
    Assignee: Institute for Molecular Biology & Biotechnology/FORTH
    Inventors: Vassilis Bouriotis, Dimitri Kafetzopoulos, John Vournakis
  • Patent number: 5124316
    Abstract: A method for promoting bone, periodontium or ligament growth of a mammal comprising applying to the bone periodontium or ligament a growth-promoting amount of a composition comprising a partially purified or purified polypeptide growth factor.
    Type: Grant
    Filed: September 13, 1990
    Date of Patent: June 23, 1992
    Assignees: President and Fellows of Harvard College, Institute of Molecular Biology, Inc.
    Inventors: Harry N. Antoniades, Samuel E. Lynch
  • Patent number: 5034375
    Abstract: Healing an external wound of a mammal by administering to the mammal a composition containing purified EGF and purified PDGF in a weight to weight ratio of at least 5:1.
    Type: Grant
    Filed: August 10, 1988
    Date of Patent: July 23, 1991
    Assignees: Institute of Molecular Biology, Inc., President and Fellows of Harvard College
    Inventors: Harry N. Antoniades, Samuel E. Lynch